Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
REGN
Regeneron Pharma
$509.72
Chart
$547.67 (-6.93%)
$640.14 (-20.37%)
$640.14 (-20.37%)
$1034.23 (-50.72%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
REGN
Regeneron Pharma
Current Price
$509.72
Login to view Regeneron Pharma (REGN) recommendation from the last 90 days from financial news and social media.
Chart
$547.67 (-6.93%)
$640.14 (-20.37%)
$640.14 (-20.37%)
$1034.23 (-50.72%)
REGN Latest Analysis
From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M. Anne Wojcicki co-founder and former CEO of 23andMe will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute the company on Friday. The deal marks the final stage in a bidding contest that began after 23andMe filed for Chapter 11 bankruptcy in March.According to the company TTAM will acquire substantially all of 23andMe'.s assets inc
Today
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with ous pemphigoid. Dupixent approved in the US as the only targeted medicine to treat patients with ous pemphigoid Patrick DunnExecutive Director International Pemphigus and Pemphigoid Foundation People affected by ous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now these primarily elderly patients have had limited therapeutic options available with potential s
Today
REGN Factor-Based Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Wed Jun 18, 2025
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process. TTAM Commits to Comply with Company'.s Privacy Policy and All Applicable LawsTTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe'.s Privacy Policy or Consumer Genome ServicesTransaction Subject to Court ApprovalSAN FRANCISCO June 13 2025 (GLOBE NEWSW
Fri Jun 13, 2025
Regeneron Pharmaceuticals Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript.
Mon Jun 9, 2025
Regeneron Pharma To Present At Goldman Sachs Global Healthcare Conference. Webcast At 10:40 AM ET . (RTTNews) - Regeneron Pharmaceuticals (REGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference.
Mon Jun 9, 2025
Is It Time To Buy Regeneron Pharmaceuticals Stock?. Regeneron Pharmaceuticals (NASDAQ:REGN) shares experienced a significant 19% drop on Friday May 30 following the unexpected failure of itepekimab its chronic obstructive pulmonary disease (COPD) treatment partnered with Sanofi in a late stage clinical trial. One of the two tr
Wed Jun 4, 2025
UBS maintains neutral rating on Regeneron stock amid pipeline news.
Tue Jun 3, 2025
Regeneron price target lowered to $600 from $800 at BMO Capital.
Tue Jun 3, 2025
Regeneron Enters In-licensing Agreement With Hansoh Pharma For HS-20094 . (RTTNews) - Regeneron Pharmaceuticals (REGN) announced an in-licensing agreement with Hansoh Pharmaceuticals to acquire clinical development and commercial rights outside of the Chinese Mainland Hong Kong and Macau for a dual GLP-1/GIP receptor agonist currently in Phase 3 testi
Mon Jun 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
REGN Stock trends
REGN Stock performance
REGN Stock analysis
REGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
